CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 1, 2018--
Therapeutics, Inc. (NASDAQ:MCRB) today announced it will present at
each of the following upcoming healthcare conferences:
- Jefferies 2018 Global Healthcare Conference: a corporate
overview will be presented on Wednesday, June 6 at 4:30 p.m. ET in New
- Goldman Sachs 39th Annual Global
Healthcare Conference: a corporate overview will be presented on
Wednesday, June 13 at 9:20 a.m. PT in Palos Verdes, CA.
A live audio webcast of each presentation will be available under the
“Investors and Media” section of Seres’ website. A replay of each
presentation will become available approximately one hour after the
event and will be archived for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. is a leading microbiome therapeutics platform
company developing a novel class of biological drugs that are designed
to treat disease by restoring the function of a dysbiotic microbiome,
where the state of bacterial diversity and function is imbalanced.
Seres’ lead program, SER-109, has obtained Breakthrough Therapy and
Orphan Drug designations from the U.S. Food and Drug Administration and
is in Phase 3 development for multiply recurrent C. difficile infection.
Seres’ clinical candidate SER-287 has successfully completed a Phase 1b
study in patients with mild-to-moderate Ulcerative Colitis. Seres is
also developing SER-262, the first ever synthetic microbiome therapeutic
candidate, in a Phase 1b study in patients with primary C. difficile
infection. For more information, please visit www.serestherapeutics.com.
Follow us on Twitter @SeresTx.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180601005213/en/
Source: Seres Therapeutics, Inc.
IR or PR:
Tanzi, Ph.D., 617-203-3467
Vice President, Investor Relations and